| Date | Title | Description |
| 22.03.2026 | Europe's Corporate Evolution: AGM Insights and Sustainability Imperatives | European firms Lundbeck and Posti Group recently unveiled key corporate updates. Lundbeck's AGM approved dividends, new board members, and a share repurchase. Posti released its 2025 Annual Report, highlighting financial results and robust ... |
| 18.03.2026 | Lundbeck held its Annual General Meeting on 18 March 2026 at the company’s registered office | Lundbeck held its Annual General Meeting on 18 March 2026 at the company’s registered office
Wed, Mar 18, 2026 13:00 CET Report this content
H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted an... |
| 16.03.2026 | Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026 | Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026
Mon, Mar 16, 2026 09:00 CET Report this content Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be prese... |
| 10.03.2026 | Lundbeck appoints Chief AI Officer | Lundbeck appoints Chief AI Officer
Tue, Mar 10, 2026 09:00 CET Report this content
Valby, Denmark, 10 March 2026 – H. Lundbeck A/S (Lundbeck) today announced the appointment of Markus Kede as Senior Vice President, Chief AI Officer. He will... |
| 09.03.2026 | Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial | Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial
Mon, Mar 09, 2026 10:33 CET Report this content MASCOT is a first-of-its-kind, Phase 3 trial supporting the development of amlenetug, an investigational th... |
| 03.03.2026 | BioInnovation Institute backs five startups with €1.3M in follow-on funding | BioInnovation Institute (BII), an initiative of the Novo Nordisk Foundation, has awarded an additional €1.3 million in follow-on funding to five portfolio startups, bringing total support per company to up to €1.8 million. The funding is in... |
| 26.02.2026 | Slate Medicines Secures $130M to Advance Migraine Prevention | Slate Medicines secures $130 million in Series A funding. The Raleigh, NC-based biotech company launched to transform migraine prevention. Its core focus is SLTE-1009, an anti-PACAP monoclonal antibody. This therapy addresses severe headach... |
| 24.02.2026 | Slate Medicines: $130 Million Series A Raised To Advance Anti-PACAP Migraine Therapies | Slate Medicines, a privately held biotech company developing next-generation therapeutics for headache disorders, has launched with the close of a $130 million Series A financing and the in-licensing of SLTE-1009, an anti-PACAP monoclonal a... |
| 18.02.2026 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Wed, Feb 18, 2026 09:32 CET Report this content
1. Details of the person discharging managerial responsibilities / person clo... |
| 17.02.2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| 12.02.2026 | Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention | Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention
Thu, Feb 12, 2026 16:39 CET Report this content The intravenous (IV) part of the phase IIb dose-finding PROCEED trial... |
| 06.02.2026 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Fri, Feb 06, 2026 11:39 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 04.02.2026 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Wed, Feb 04, 2026 19:13 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 04.02.2026 | Lundbeck Annual Report 2025 | Lundbeck Annual Report 2025
Wed, Feb 04, 2026 07:50 CET Report this content
Annual report 2025 in XHTML format submitted to the Danish Financial Supervisory Authority (The Officially Appointed Mechanisms)
H. Lundbeck A/S
Ottiliavej 9, 2500 ... |
| 04.02.2026 | Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026 | Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026
Wed, Feb 04, 2026 07:30 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +13% CER[1] (+12%... |
| 30.01.2026 | Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference | Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
Fri, Jan 30, 2026 15:00 CET Report this content New six-month r... |
| 26.01.2026 | €76 million Footprint Fund I to support 30 early-stage climate and DeepTech companies across Northern Europe | “With Footprint Fund I, we are doubling down on our mission to accelerate what is necessary,” said Anna Søndergaard, co-founding Partner and CEO at The Footprint Firm. “The future worth building will not arrive by chance, it must be venture... |
| 31.12.2025 | M&A deals won’t break 2024 record | Last year’s megadeals meant 2025 had a tough act to follow. Gerry Byrne finds that while transactions are at a similar level to 2024, the value of M&A activity in the last 12 months is unlikely to reach the same peak
Despite the number ... |
| 08.12.2025 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Mon, Dec 08, 2025 08:22 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 06.12.2025 | Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting | Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Sat, Dec 06, 2025 18:00 CET Report this content New long-term data presented at AES 202... |
| 02.12.2025 | Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting | Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Tue, Dec 02, 2025 08:00 CET Report this content New data to be presented at the 20... |
| 26.11.2025 | ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RU... | ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”)
Wed, Nov 26, 2025 17:23 CET Report... |
| 14.11.2025 | ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND MAR ARTICLE 17 (INSIDE INFORMATION) | ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND MAR ARTICLE 17 (INSIDE INFORMATION)
Fri, Nov 14, 2025 12:44 CET Report this content
NOT FOR RELEASE, PUBL... |
| 14.11.2025 | Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine | Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for pat... |
| 14.11.2025 | Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine | Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
Fri, Nov 14, 2025 08:55 CET Report this content Lundbeck's new drug application (NDA) for Vyepti® (eptine... |
| 13.11.2025 | Nasdaq closes higher, snapping three-day losing streak as tech stocks recover some ground | The Nasdaq Composite rebounded on Friday as investors bought up shares of key technology stocks a day after the group led Wall Street to its worst day in more than a month.
The tech-heavy Nasdaq gained 0.13% to finish at 22,900.59, snapping... |
| 12.11.2025 | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments | VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights
Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. and Europe was the driver of this strong perform... |
| 11.11.2025 | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments | Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments
Tue, Nov 11, 2025 15:34 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +14% CER[1... |
| 11.11.2025 | Lundbeck raises financial guidance for 2025 | Lundbeck raises financial guidance for 2025
Tue, Nov 11, 2025 15:21 CET Report this content
H. Lundbeck A/S (Lundbeck) increases its full-year 2025 financial guidance for both revenue and adjusted EBITDA growth at constant exchange rates (C... |
| 27.10.2025 | Lundbeck and OpenAI join forces to unlock innovation and boost productivity | Lundbeck and OpenAI join forces to unlock innovation and boost productivity
Mon, Oct 27, 2025 09:00 CET Report this content
Valby, Denmark, 27 October 2025 – H. Lundbeck A/S (Lundbeck) today announced a strategic collaboration with OpenAI t... |
| 20.10.2025 | Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions | Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions
Mon, Oct 20, 2025 09:00 CET Report this content
Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) ... |
| 13.10.2025 | Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies | Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies
Mon, Oct 13, 2025 08:00 CET Report this content Accelerated pathway underscores urgent need for innovative sol... |
| 13.10.2025 | Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies | Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies
Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental... |
| 02.10.2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson’s Disease and Movement Disorders® 2025
Thu, Oct 02, 2025 09:00 CET Report this content Details of the Phase 3 M... |
| 02.10.2025 | Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025 | Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3
MSA is a rar... |
| 20.09.2025 | Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD | Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD
Sat, Sep 20, 2025 08:00 CET Report this content
Valby, Denmark, 20 ... |
| 11.09.2025 | Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine | Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on epti... |
| 11.09.2025 | Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine | Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Thu, Sep 11, 2025 08:00 CET Report this content Lundbeck demonstrates leadership ... |
| 09.09.2025 | Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025 | Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025
Tue, Sep 09, 2025 14:30 CET Report this content Three new regional partnerships will secure continuity of today’s commercial activities... |
| 25.08.2025 | Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy | The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at th... |
| 25.08.2025 | Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy | Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
Mon, Aug 25, 2025 09:00 CET Report this content The full results of the open label extension... |
| 13.08.2025 | Guidance raised based on solid H1 results and continued strong expectations for the full year 2025 | Guidance raised based on solid H1 results and continued strong expectations for the full year 2025
Wed, Aug 13, 2025 18:40 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +14% CER[1] (+14% DKK) to DKK 12,258 million ... |
| 13.08.2025 | Lundbeck raises financial guidance for 2025 | Lundbeck raises financial guidance for 2025
Wed, Aug 13, 2025 18:34 CET Report this content
H. Lundbeck A/S (Lundbeck) raises the financial guidance for the full-year revenue and adjusted EBITDA growth at constant exchange rates (CER).
Lund... |
| 06.08.2025 | Named 'Great Place to Work,' Moon Rabbit Reports Record Growth, New Clients, Industry Accolades | Moon Rabbit
Independent agency forges key industry partnerships, hires 28 new employees to fuel expansion
NEW YORK, Aug. 6, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and health... |
| 22.07.2025 | Hacking the Immune System for Brain Drug Delivery: Interview with Adaptin Co-Founder and CEO Michael Roberts | Share
Share
Share
Share
Email
The blood-brain barrier (BBB) has long stood as one of the greatest challenges in medicine, thwarting efforts to deliver therapeutics to the brain and leaving many neurological conditions with few effective tre... |
| 19.07.2025 | Otsuka, Lundbeck’s PTSD Drug Fails to Win US FDA Panel Support | - |
| 18.07.2025 | Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD) | Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)
Fri, Jul 18, 2025 23:24 CET Report this content
Valby, Denmark, 18 July 202... |
| 24.06.2025 | Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia | Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
Tue, Jun 24, 2025 08:00 CET Report this content
Congenital adrenal hyperplasia (CAH) is a rare autos... |
| 23.06.2025 | Eptinezumab: A New Dawn for Chronic Migraine Sufferers | Chronic migraine is a relentless storm, battering the lives of millions. For those caught in its grip, the search for relief can feel like navigating a maze with no exit. However, recent breakthroughs in migraine treatment, particularly wit... |
| 21.06.2025 | New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine | New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
Sat, Jun 21, 2025 13:20 CET Report this content The full results of the phase III registrational SUNRISE trial were presented... |
| 21.06.2025 | New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine | New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
Sat, Jun 21, 2025 13:25 CET Report this content The full results of the phase IV RESOLUTION trial were presented at... |
| 22.05.2025 | Lundbeck successfully places a EUR 500 million Eurobond | Lundbeck successfully places a EUR 500 million Eurobond
Thu, May 22, 2025 17:31 CET Report this content
Valby, Denmark, 22 May 2025 - H. Lundbeck A/S (Lundbeck) has successfully placed an aggregate principal amount of EUR 500 million senior... |
| 09.05.2025 | Winter Wellness: A Guide for Seniors to Thrive in Cold Weather | Winter is a double-edged sword. It brings beauty and wonder, but it also poses challenges, especially for seniors. As the temperature drops, the risks rise. Icy sidewalks become treacherous, and the cold can seep into homes, leading to heal... |
| 08.05.2025 | Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston | Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston
Thu, May 08, 2025 08:00 CET Report this content
H. Lundbeck A/S (Lundbeck) will present ... |
| 06.05.2025 | Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer | Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer
Tue, May 06, 2025 08:00 CET Report this content
H. Lundbeck A/S is pleased to announce its agreement... |
| 05.04.2025 | Lundbeck's Bold Moves in Migraine and Epilepsy Treatments: A New Dawn for Patients | In the world of pharmaceuticals, innovation is the lifeblood. Lundbeck, a biopharmaceutical company, is making waves with its latest developments in migraine and epilepsy treatments. The company is expanding its research horizons, aiming to... |
| 04.04.2025 | Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting | Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting
Fri, Apr 04, 2025 09:00 CET Report this content
H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension ... |
| 31.03.2025 | Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention | Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention
Mon, Mar 31, 2025 11:00 CET Report this content PROCEED is an adaptive Phase IIb ... |
| 28.03.2025 | The Future of Health and Food: Innovations in Pharmaceuticals and Precision Fermentation | In the fast-paced world of health and nutrition, two recent developments stand out. One is a groundbreaking partnership in pharmaceuticals, while the other is a leap forward in food technology. Both aim to tackle pressing global issues: chr... |
| 27.03.2025 | Melt&Marble Strengthens Leadership to Scale Precision-Fermented Fat Production | Melt&Marble, a company specializing in precision-fermented fats, has announced two significant additions to its leadership team as it prepares for large-scale commercial production.
Tue Hodal, a veteran of industrial biotech and pharma,... |
| 26.03.2025 | Lundbeck held its Annual General Meeting on 26 March 2025 at the company’s registered office | Lundbeck held its Annual General Meeting on 26 March 2025 at the company’s registered office
Wed, Mar 26, 2025 12:28 CET Report this content
H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted an... |
| 13.03.2025 | Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older | Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Thu, Mar 13, 2025 09:00 CET Report this content
Brexpiprazole’s indication for the treatment of schizophrenia... |
| 12.03.2025 | The Future of Neurorehabilitation: Innovations and Breakthroughs | In the world of healthcare, innovation is the lifeblood that keeps the industry thriving. Recently, two remarkable developments have emerged in the realm of neurorehabilitation. One is a groundbreaking software startup that harnesses augmen... |
| 10.03.2025 | Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan | Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
Mon, Mar 10, 2025 09:01 CET Report this content
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designati... |
| 10.03.2025 | Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan | VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Mu... |
| 25.02.2025 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 25, 2025 10:00 CET Report this content Notice of Annual General Meeting
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: Wednesday, 26 March 2025 at 10:00... |
| 21.02.2025 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Fri, Feb 21, 2025 13:27 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 19.02.2025 | Moon Rabbit Wraps 2024 with Key Executive Hires, New NYC Headquarters, Major Client Wins | Healthcare agency also won Fierce Pharma's 'Best New Brand Launch' award, opened London office, instituted workplace enhancements for expanding team
NEW YORK, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and m... |
| 12.02.2025 | Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA | Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
Wed, Feb 12, 2025 09:00 CET Report this content
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug,... |
| 05.02.2025 | ECTFE: The New Vanguard in Chemical Transport | In the world of industrial piping, the stakes are high. The transport of aggressive chemicals is akin to navigating a minefield. One wrong move, and the consequences can be catastrophic. Traditional materials like PFA and stainless steel ha... |
| 05.02.2025 | Lundbeck Annual Report 2024 | Lundbeck Annual Report 2024
Wed, Feb 05, 2025 07:46 CET Report this content
Annual report 2024 in XHTML format submitted to the Danish Financial Supervisory Authority (The Officially Appointed Mechanisms)
H. Lundbeck A/S
Ottiliavej 9, 2500 ... |
| 05.02.2025 | Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER) | Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)
Wed, Feb 05, 2025 07:23 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +14% CER[1] (+11% DKK) to DKK ... |
| 05.02.2025 | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties | Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Wed, Feb 05, 2025 16:40 CET Report this content
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by ... |
| 04.02.2025 | Illinois Biotechnology Innovation Organization Appoints Three Industry Leaders to Board of Directors | The Illinois Biotechnology Innovation Organization (iBIO), the premier trade association representing the state's vibrant life sciences sector with 94,000 jobs, today announced the appointment of three accomplished industry leaders to its b... |
| 04.02.2025 | Lundbeck announces changes to the Board of Directors | Lundbeck announces changes to the Board of Directors
Tue, Feb 04, 2025 17:10 CET Report this content
Lundbeck announces changes to the Board of Directors Lars Søren Rasmussen, Chair of Lundbeck’s Board of Directors, has decided not to seek ... |
| 30.01.2025 | Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies | Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies
Thu, Jan 30, 2025 09:00 CET Report this content
Bexic... |
| 09.01.2025 | Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD | Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD
Thu, Jan 09, 2025 14:07 CET Report this content
H. Lundbeck A/S (Lundbeck)... |
| 05.12.2024 | Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations | Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations
Thu, Dec 05, 2024 13:00 CET Report this content
Longboard Pharmaceuticals, now a wholly owned subsidiary... |
| 03.12.2024 | Efficacy of Vyepti highlighted by new clinical trial results in severe migraine | Efficacy of Vyepti highlighted by new clinical trial results in severe migraine
Tue, Dec 03, 2024 08:00 CET Report this content
New results from the RESOLUTION trial demonstrate the efficacy of Vyepti® (eptinezumab) on top of patient educat... |
| 02.12.2024 | Lundbeck completes acquisition of Longboard | Lundbeck completes acquisition of Longboard
Mon, Dec 02, 2024 15:08 CET Report this content A significant step forward in Lundbeck’s Focused Innovator strategy and advancing the goal of building a robust neuro-rare franchise The lead asset,... |
| 28.11.2024 | Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled | Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled
Thu, Nov 28, 2024 07:56 CET Report this content A significant step forward in Lundbeck’s Focused Innovator strategy and advancing the... |
| 27.11.2024 | Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy | Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy
Wed, Nov 27, 2024 08:00 CET Report this content
MASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the ... |
| 13.11.2024 | Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 | Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024
Wed, Nov 13, 2024 07:29 CET Report this content
Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in th... |
| 31.10.2024 | Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention | Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention
Thu, Oct 31, 2024 12:44 CET Report this content Vyepti® confirms efficacy in new phase III pivotal SUNRISE trial, mee... |
| 17.10.2024 | Lundbeck makes huge bid for Longboard | Lundbeck makes huge bid for Longboard
Thu, Oct 17, 2024 08:45 CET Report this content
Danish Lundbeck has made a bid for American Longboard Pharmaceuticals worth USD 2.6 billion. With this deal, they would get access to Bexicaserin, a promi... |
| 15.10.2024 | Access Bank's Sustainable Finance Accelerator: A Green Light for Nigeria's Future | In a world grappling with climate change, Access Bank Plc has taken a bold step. The bank recently launched its Sustainable Finance Accelerator Program, a beacon of hope for eco-friendly initiatives in Nigeria. This program aims to empower ... |
| 15.10.2024 | Датская компания Lundbeck приобретает американского разработчика лекарства от эпилепсии за $2,6 млрд | Сделка расширяет портфель услуг копенгагенской компании Lundbeck по лечению неврологических заболеваний, таких как болезнь Паркинсона, мигрень и болезнь Альцгеймера.
Lundbeck прогнозирует потенциальный мировой пик продаж в размере $1,5–2 мл... |
| 14.10.2024 | Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline | Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline
Mon, Oct 14, 2024 12:30 CET Report this content The proposed acquisition represents a significant step forward in Lundbeck’... |
| 03.10.2024 | Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease | Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease
Thu, Oct 03, 2024 09:00 CET Report this content
H. Lundbeck A/S (Lundbeck) today announced taking one further step in developing treatments for indication... |
| 30.09.2024 | Barbara Corcoran Needed to Make Job Cuts. Here's Why She Fired Her Mom First. Barbara Corcoran sat down with Entrepreneur and talked about the tough calls she had to make while running The Corcoran Gr... | Barbara Corcoran remembers when her real estate firm, The Corcoran Group, was in a tight spot. Mortgage rates were around 18%, placing the date around October 1981. She knew she had to make job cuts.
"My mother said to me, 'You're goin... |
| 27.09.2024 | Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders | Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders
Fri, Sep 27, 2024 14:00 CET Report this content
Lundbeck advances its commitment to addressing the... |
| 26.09.2024 | Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery | Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery
Thu, Sep 26, 2024 12:00 CET Report this content
Lundbeck partners with Iambic to utilize its AI-powered drug discovery platform to accelerate ... |
| 20.09.2024 | Navigating the Warrant Landscape: A Look at Brain+ and Diagonal Bio | In the world of finance, warrants are like keys to a treasure chest. They offer investors the chance to unlock new shares at a predetermined price. Recently, two companies, Brain+ A/S and Diagonal Bio AB, have made headlines with their warr... |
| 17.09.2024 | Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4 | Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4
Tue, Sep 17, 2024 10:46 CET Report this content
Copenhagen, Denmark, 17 September 2024 – Brain+ A/S (Nasdaq First North: BR... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 28.08.2024 | SAS announces designated Board of Directors | SAS announces designated Board of Directors
Wed, Aug 28, 2024 17:00 CET Report this content
The new principal investors in SAS, Castlelake, Air France-KLM, Lind Invest and the Danish State, have agreed to appoint a new Board of Directors fo... |
| 21.08.2024 | Lundbeck's Financial Surge: A Beacon of Growth in Neuroscience | Lundbeck, the Danish biopharmaceutical company, is riding a wave of success. The company recently raised its financial guidance for 2024, a clear signal that its strategic brands are thriving. This growth story is not just about numbers; it... |
| 20.08.2024 | Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator | Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator
Tue, Aug 20, 2024 09:09 CET Report this content
Key highlights
Lundbeck’s total revenue grew by +10% C... |
| 20.08.2024 | Lundbeck raises financial guidance for 2024 | Lundbeck raises financial guidance for 2024
Tue, Aug 20, 2024 08:53 CET Report this content
Valby, Denmark, August 20, 2024 - H. Lundbeck A/S (Lundbeck) announced revenue and adjusted EBITDA growth at constant exchange rates (CER) for the f... |